AllDocs -> cancers

Fox Chase Cancer Center 2005 Scientific Report 1 Monica Morrow, M.D., F.A. Elin R. Sigurdson, M.D., Ph.D., Senior Member John P. Hoffman, M.D., F.A.C.S., Senior Member Natalie E. Joseph, M.D ., Associate Member Neal S.Topham, M.D., Associate Member James C. Watson, M.D., Associate Member Cathy O’Hare, Senior Medical Secretary Susan Davis, Medical Secretary In the United States in the last year, there were more than 250,000 cases of gastrointestinal cancer , with more than 135,000 deaths from these diseases. Gastrointestinal malignancies include cancers of the esophagus, stomach, hepatobiliary system, pancreas, and small and large intestines. The most common gastrointestinal cancer in men and women is colorectal cancer , and is the second leading cause of ...

TNFerade TM Combined with Chemoradiation in Gastrointestinal Cancer : Phase I/II Studies in Unresectable Locally Advanced Pancreatic and Resectable Esophageal Cancer Neil Senzer, MD Scientific Director Mary Crowley Medical Research Center US Oncology, Dallas, TX On behalf of the TNFerade TM Investigators Page 2 What is TNFerade TM ? • TNFerade is a second-generation (E1-, partial E3-, and E4-deleted) adenovector carrying the transgene encoding for TNF- a • A radiation-inducible promoter (Egr-1) is incorporated in the construct to optimize spatial and temporal gene expression following ionizing radiation Page 3 Rationale of TNFerade and Radiation Therapy Transcriptional targeting using a radiation- inducible, radio-sensitizing ...

Cambridge-Munich Upper Gastrointestinal Cancer Workshop Trinity College Cambridge March 28 th to 30 th 2004 Preliminary Programme Sunday 28 th March Afternoon - Tour of colleges Evening - Trinity College Drinks reception Guest lecture: Molecular imaging Professor Kevin Brindle, Biochemistry Department, Cambridge Informal buffet supper Page 2 Monday 29 th March Introduction and aims of the workshop : Carlos Caldas and Heinz Hoefler Morning session 1 – Genetic susceptibility to upper GI cancers Caldas (Oncology, Cambridge) Hereditary diffuse gastric cancer Keller/Vogelsang (Pathology, Munich) Familial gastric cancer Pharoah (Oncology, Cambridge) Low penetrance susceptibility genes - Stomach Oesophageal Cancer Study ...

THE PHASE 2 AND 3 GASTROINTESTINAL CANCER PIPELINE Information for this chart was gathered from the Pharmaceutical Research and Manufacturers of America, corporate Web sites, meeting abstracts, and the databases of H EM /O NC T ODAY . The publisher or editors do not assume responsibility for any errors or omissions. Compiled by Kristine Welsh, Associate Editor Generic Name Product Name Company Indication Phase Anti-gastrin therapeutic vaccine Not yet available Aphton Corporation Colorectal cancer ; pancreatic cancer ; stomach Phase 2/3 cancer ; esophageal cancer ; liver cancer Anti-idiotype antibody TriGem Titan Pharmaceuticals Colorectal cancer Phase 2 Anti-VEGF Not yet available Genetech Colorectal cancer Phase 3 Autologous vaccine OncoVAXCL ...